Neuropathic pain in the IMI-APPROACH knee osteoarthritis cohort: prevalence and phenotyping.
Eefje Martine van HelvoortPaco M J WelsingMylene P JansenWillem Paul GielisMarieke LoefMargreet KloppenburgFrancisco BlancoIda K HaugenFrancis BerenbaumAnne-C Bay-JensenChristoph LadelAgnes LalandeJonathan LarkinJohn LoughlinAli MobasheriHarrie WeinansFloris LafeberNiels EijkelkampSimon MastbergenPublished in: RMD open (2022)
OA patients with a likely NP component, as determined with the painDETECT questionnaire, may represent a specific OA phenotype, where local and overall joint damage is not the main cause of pain and disability. Patients with this NP component will likely not benefit from general pain medication and/or disease-modifying OA drug (DMOAD) therapy. Reserved inclusion of these patients in DMOAD trials is advised in the quest for successful OA treatments.Trial registration numberThe study is registered under clinicaltrials.gov nr: NCT03883568.
Keyphrases
- knee osteoarthritis
- neuropathic pain
- spinal cord
- spinal cord injury
- chronic pain
- end stage renal disease
- newly diagnosed
- pain management
- multiple sclerosis
- prognostic factors
- healthcare
- study protocol
- high throughput
- risk factors
- clinical trial
- emergency department
- stem cells
- patient reported
- phase iii
- cross sectional